Psychiatry has long grappled with the question of whether mental illnesses possess distinct hereditary signatures or represent diffuse genetic liabilities broadly predisposing individuals to a spectrum of psychiatric conditions. The debate dates back to the 19th century when early family studies ignited fierce contention over the nature of hereditary risk transmission. While modern techniques such as twin studies, molecular genetics, and polygenic risk scoring have demonstrated notable overlap in genetic risk factors among disorders like schizophrenia, bipolar disorder, depression, and substance use, the question of quantifying this overlap numerically has remained elusive — until now.

Dr. Kendler’s team devised an incisive methodological framework to tackle this challenge by focusing on nine diagnostically diverse psychiatric and substance use disorders: schizophrenia, bipolar disorder, alcohol use disorder, ADHD, autism spectrum disorder, PTSD, major depression, anxiety disorder, and drug use disorder. They computed family genetic risk scores (FGRS) from detailed morbidity patterns observed across relatives spanning five degrees of kinship. Importantly, analyses accounted for environmental confounders such as shared household effects. Through linear regression, the researchers isolated what fraction of the overall genetic signal in each diagnostic group was attributable specifically to that diagnosis, thereby assigning a precise “genetic specificity” value to each disorder.

The scope of this population-based study is unprecedented. Sample sizes ranged from tens of thousands for rarer diagnoses like schizophrenia (approximately 18,348 cases) to hundreds of thousands for more common disorders such as depression (674,955 cases). The encompassing Swedish registries provided a comprehensive dataset with robust diagnostic validity, enabling what may be the most definitive quantification of genetic specificity to date.

The results reveal a striking hierarchy that challenges existing psychiatric nosology. Schizophrenia topped the specificity scale with 73.1%, indicating that nearly three-quarters of the genetic liability in diagnosed individuals is unique to schizophrenia itself. Bipolar disorder followed with a moderate 54.8%, and alcohol use disorder registered similarly at 54.1%. A mid-level specificity cluster comprising ADHD, autism spectrum disorder, and PTSD hovered just below 50%, despite their distinct clinical presentations.

At the lower end of the spectrum, major depression, anxiety disorder, and especially drug use disorder exhibited markedly reduced genetic specificity, with drug use disorder’s specificity at a mere 29.5%. This suggests that a large proportion of genetic risk in drug use disorder is not disorder-specific but rather overlaps extensively with risks for schizophrenia, mood disorders, ADHD, and others. Such revelations bear profound implications, implying that some disorders may represent more genetically “pure” entities whereas others are downstream manifestations of broader, shared genetic vulnerabilities.

Beyond these static values, perhaps the most transformative discovery concerns the dynamism of genetic specificity itself. The research elegantly demonstrates that specificity fluctuates according to clinical parameters well-known to psychiatrists: age at onset, recurrence frequency, and treatment environment. Bipolar disorder exemplified this plasticity; early-onset cases exhibited significantly higher genetic specificity compared to late-onset cases, and patients with recurrent episodes showed elevated specificity compared to those with isolated episodes. Moreover, bipolar patients hospitalized for treatment had markedly higher specificity than those managed solely in primary care, with differences exceeding 30 percentage points.

Interestingly, PTSD displayed an inverse relationship, with later onset and outpatient care correlating with increased specificity. Across all conditions examined, greater recurrence uniformly predicted higher genetic specificity, underscoring that repeated episodes may serve as a clinical marker of genetically concentrated liability rather than generalized psychiatric vulnerability.

Delving deeper into clinical nuances, the study revealed contrasting genetic specificity patterns between depression and bipolar disorder relative to treatment settings. Hospitalized bipolar cases, likely admitted due to classic manic episodes, showed high disorder-specific genetic liability. Conversely, hospitalized depression cases manifested lower specificity, likely attributable to severe behavioral complications—such as suicidal ideation and substance misuse—that incorporate externalizing genetic influences. This dichotomy poses critical questions for research design: should depression genetic studies preferentially recruit from primary care to capture cleaner mood-related signals, while bipolar studies focus on inpatient samples?

Robust sensitivity analyses further bolster confidence in these findings. Adjustments for comorbid diagnoses minimally shifted specificity estimates, even after excluding cases with overlapping bipolar and depressive diagnoses. Sex-based analyses showed comparable specificity levels across genders for most disorders, except for alcohol and drug use disorders where males demonstrated significantly higher specificity — a difference the authors speculate might reflect socio-environmental influences attenuating genetic signals differently between men and women.

The team also performed leave-one-out analyses to examine interdependencies among disorders, uncovering expected genetic overlaps between highly correlated disorder pairs like depression-anxiety and alcohol-drug use disorders. These patterns confirm that specificity estimates inherently depend on the constellation of disorders considered, aligning with prior genetic epidemiology literature.

Compellingly, these findings dovetail with independent molecular genetic research. A recent 2026 Nature study led by Grotzinger identified a general psychopathology “P-factor” encompassing shared genetic variance across numerous psychiatric conditions, grouping disorders with low genetic specificity (depression, anxiety, PTSD) under internalizing subfactors strongly linked to this global factor. In contrast, schizophrenia and bipolar disorder formed a more distinct factor with relatively modest ties to the P-factor, mirroring the specificity gradients observed by Kendler and colleagues. The convergence of results drawn from divergent datasets and methodologies significantly strengthens the validity of genetic specificity as a meaningful construct.

Nevertheless, several limitations merit acknowledgment. Reliance on registry diagnoses, though extensive and validated, lacks the granularity of structured clinical interviews. Family genetic risk scores differ conceptually from polygenic risk scores derived from genomic sequencing, though prior work suggests functional concordance. The largely Scandinavian cohort raises questions about generalizability to other populations with different genetic backgrounds or health care systems. Moreover, the ever-present influence of comorbidity inherently shapes specificity, as disorders with high shared comorbidity and modest heritability (like depression) naturally yield lower specificity compared to highly heritable, less comorbid illnesses (schizophrenia).

Looking ahead, the implications for psychiatric genetics and clinical practice are extensive. Researchers can refine participant selection to either amplify or attenuate genetic specificity, depending on study aims. Clinicians may harness observable clinical features—age at onset, recurrence, and treatment setting—as proxies to infer underlying genetic architecture, potentially guiding prognosis and personalized interventions. Perhaps most importantly, the quantitative framework supplied by this study offers a novel tool for revisiting psychiatric classification systems with genetic clarity, moving beyond phenotypic symptom clusters toward genetically informed diagnoses.

Dr. Kendler aptly sums up the transformative nature of this work: “For over a century, we have debated whether psychiatric disorders are distinct biological entities or overlapping spectra. Now, for the first time, we can assign concrete numbers to these questions—some disorders cleave the genetic landscape clearly, while others blend extensively. Our findings compel clinicians and researchers to gauge diagnostic categories not just by symptoms but by their underlying genetic specificity.”

This landmark investigation not only advances psychiatric genetics by illuminating the heterogeneous genetic constitution of mental illness, but it also exemplifies how interdisciplinary collaboration and large-scale population science can bridge molecular biology, epidemiology, clinical psychiatry, and public health. Open Access publication in Genomic Psychiatry ensures that these insights will catalyze further research, shaping the future of psychiatric nosology and precision medicine.

Subject of Research: People

Article Title: The specificity of genetic risk for psychiatric and substance use disorders: Its modification by age at onset, recurrence, and site of treatment

News Publication Date: 3-Mar-2026

Web References: https://doi.org/10.61373/gp026a.0024

Image Credits: Kenneth S. Kendler

Keywords: Genetic specificity, psychiatric genetics, schizophrenia, bipolar disorder, substance use disorder, family genetic risk scores, psychiatric classification, recurrence, age at onset, treatment setting, comorbidity, population-based study

The methodology centered around Local Analysis of (Co)variant Association (LAVA), which partitions the genome and evaluates genetic correlations (r_g) within each block. This approach transcends traditional genome-wide methods that average genetic overlap and potentially obscure important regional variation. By imposing stringent heritability thresholds and multiple-testing corrections, the study identified 458 statistically significant pairwise local genetic correlations between disorder pairs. The vast majority of these r_g estimates were positive, reinforcing the notion that increased genetic risk for one psychiatric condition typically heightens vulnerability for others—a key insight into the intertwined nature of mental illness etiology.

Prominent among disorder pairs with the largest numbers of significant local correlations were Major Depression (MD) with Anxiety Disorders (ANX), MD with Post-Traumatic Stress Disorder (PTSD), and Bipolar Disorder (BIP) with Schizophrenia (SCZ). These findings harmonize with broader genetic overlap indicated by genome-wide linkage disequilibrium score regression (LDSC) and polygenic overlap analyses, underscoring consistent genetic pathways shared across major psychiatric phenotypes. The discovery of both global and local r_g landscapes illustrates a pervasive positive genetic interconnection, with very few instances of negative correlations, highlighting the complex but cooperative genetic interplay shaping mental health disorders.

Of particular note, the researchers identified 101 genomic “hotspots”—regions exhibiting significant pleiotropic genetic correlations across multiple psychiatric disorders. The most remarkable hotspot resides on chromosome 11, spanning base pairs 112,755,447 to 114,742,317. This locus displayed 17 significant and positive local r_g associations involving eight of the fourteen disorders studied, making it a nexus of genetic risk. This chromosomal segment also featured among the top loci associated with the majority of these disorder pairs, suggesting a critical hub of genetic influence.

This region on chromosome 11 encompasses the well-studied NCAM1–TTC12–ANKK1–DRD2 gene cluster, a genetic constellation repeatedly implicated in various psychiatric and behavioral phenotypes. Previous research has connected variants in this cluster to neuropsychiatric conditions including Attention Deficit Hyperactivity Disorder (ADHD), nicotine dependence, and suicidal behavior. The current findings reinforce and expand the significance of this locus, positioning it as a central player in the shared genetic architecture underlying diverse psychiatric disorders.

By leveraging the LAVA framework within finely partitioned LD segments, the study affords unparalleled resolution in detecting not only significant genetic correlations but also their spatial clustering across the genome. This local r_g mapping enriches our understanding of pleiotropy, illuminating genetic hotspots where pathogenic effects may converge. Such insights could catalyze precision medicine strategies, enabling targeted research on these key genomic regions to decipher mechanistic pathways and inform therapeutic interventions.

Contrasting with the dominance of positive genetic correlations, only three instances of significant negative local r_g were detected. This scarcity suggests that, in most cases, genetic factors conferring risk to one psychiatric disorder do not simultaneously protect against another, but rather promote comorbidity or symptom overlap. This revelation challenges simplistic models of psychiatric genetics and highlights the necessity for nuanced exploration of individual genetic variants’ pleiotropic effects.

The study’s integration of genome-wide estimates, local correlation analyses, and network modeling depicts a complex, interconnected psychiatric genomic landscape. Disorders sharing a factor structure in genomic structural equation modeling also tend to cluster geographically within the local r_g network plots, reflecting biologically meaningful relationships. This concordance bolsters confidence in the multi-layered analytic strategy and encourages application of similar frameworks in future psychiatric genetics research.

Moreover, the delineation of disorder-specific and pleiotropic loci invites reevaluation of current nosological boundaries. Genetic hotspots implicating multiple disorders suggest shared etiological underpinnings, potentially informing revised classifications reflective of underlying biology rather than purely clinical symptomatology. Such a shift could transform diagnostic practices and facilitate cross-disorder therapeutic development.

This research advances the frontier of psychiatric genetics by precisely mapping where and how genetic risk overlaps across numerous mental health conditions within the human genome. The identification of robust, highly pleiotropic regions like the chromosome 11 locus provides fertile ground for functional follow-up studies. Understanding the behavior of genes within these hotspots may unlock critical pathways mediating broad psychiatric vulnerability, ultimately guiding novel intervention strategies.

The implications extend beyond psychiatry, as pleiotropy hotspots often harbor genes influencing cognitive traits, personality dimensions, substance use, and sleep patterns. This multidimensional genetic interrelation underscores the complexity of brain function and its susceptibility to diverse perturbations. Future endeavors integrating genomic data with transcriptomic and epigenomic profiles promise to elucidate the mechanistic cascades linking genotype to psychiatric phenotype.

This study exemplifies the power of integrating rigorous statistical genetics with biomedically informed genomic segmentation to disentangle the polygenic architecture of complex psychiatric traits. By moving beyond global averages to local genetic landscapes, the authors highlight the heterogeneity and specificity inherent in psychiatric genetic risk, advancing both conceptual frameworks and practical methodologies.

Collectively, these findings reshape our understanding of psychiatric disorder genetics, revealing a mosaic of interconnected genetic influences spread variably across the genome. The elucidation of local r_g hotspots offers a roadmap to targeted gene discovery and functional validation. As genetic research marches forward, such finely resolved maps are indispensable for translating genomic knowledge into clinical precision psychiatry.

In summation, this pioneering investigation maps the intricate web of local genetic correlations that knit together the genetic risk profiles of a broad spectrum of psychiatric disorders. Identifying both shared genetic burdens and disorder-specific components will pave the way for a more integrated and biologically grounded classification of mental health conditions, fostering advances across diagnosis, treatment, and prevention in psychiatric medicine.

Subject of Research: Mapping the local genetic correlations and pleiotropy across 14 psychiatric disorders.

Article Title: Mapping the genetic landscape across 14 psychiatric disorders.

Article References:
Grotzinger, A.D., Werme, J., Peyrot, W.J. et al. Mapping the genetic landscape across 14 psychiatric disorders. Nature (2025). https://doi.org/10.1038/s41586-025-09820-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-025-09820-3